Application of Dynamic \(^{18}\)F-FDG PET/CT for Distinguishing Intrapulmonary Metastases from Synchronous Multiple Primary Lung Cancer

Weize Lv, Min Yang, Hongcheng Zhong, Xiaojin Wang, Shuai Yang, Lei Bi, Jianzhong Xian, Xiaofeng Pei, Xinghua He, Ying Wang, Zhong Lin, Qingdong Cao, Hongjun Jin, and Hong Shan

1Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China
2Department of Medical Oncology, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China
3Department of Cardiothoracic Surgery, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China
4Department of Ultrasound, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China
5Nuclear Medicine Department, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China
6Interventional Department, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China

Correspondence should be addressed to Hongjun Jin; jinhj3@mail.sysu.edu.cn

Received 1 December 2021; Revised 27 February 2022; Accepted 7 June 2022; Published 30 June 2022

Academic Editor: Henry VanBrocklin

Copyright © 2022 Weize Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

It has been a big challenge to distinguish synchronous multiple primary lung cancer (sMPLC) from primary lung cancer with intrapulmonary metastases (IPM). We aimed to assess the clinical application of dynamic \(^{18}\)F-FDG PET/CT in patients with multiple lung cancer nodules. We enrolled patients with multiple pulmonary nodules who had undergone dynamic \(^{18}\)F-FDG PET/CT and divided them into sMPLC and IPM groups based on comprehensive features. The SUV\(_{\text{max}}\), fitted \(K_i\) value based on dynamic scanning, and corresponding maximum diameter (\(D_{\text{max}}\)) from the two largest tumors were determined in each patient. We determined the absolute between-tumor difference of \(\Delta\text{SUV}_{\text{max}}/D_{\text{max}}\) and \(\Delta\text{Ki}/D_{\text{max}}\) and assessed the between-group differences. Further, the diagnostic accuracy was evaluated by ROC analysis and the correlation between \(\Delta\text{SUV}_{\text{max}}/D_{\text{max}}\) and \(\Delta\text{Ki}/D_{\text{max}}\) from all groups was determined. There was no significant difference for \(\Delta\text{SUV}_{\text{max}}/D_{\text{max}}\) between the IPM and sMPLC groups, while the IPM group had a significantly higher \(\Delta\text{Ki}/D_{\text{max}}\) than the sMPLC group. The AUC of \(\Delta\text{Ki}/D_{\text{max}}\) for differentiating sMPLC from IPM was 0.80 (cut-off value of \(K_i = 0.0059\), sensitivity 79%, specificity 75%, \(p < 0.001\)). There was a good correlation (Pearson \(r = 0.91\), 95% CI: 0.79-0.96, \(p < 0.0001\)) between \(\Delta\text{SUV}_{\text{max}}/D_{\text{max}}\) and \(\Delta\text{Ki}/D_{\text{max}}\) in the IPM group but not in the sMPLC group (Pearson \(r = 0.45, p > 0.05\)). Dynamic \(^{18}\)F-FDG PET/CT could be a useful tool for distinguishing sMPLC from IPM. \(K_i\) calculation based on Patlak graphic analysis could be more sensitive than \(\text{SUV}_{\text{max}}\) in discriminating IPM from sMPLC in patients with multiple lung cancer nodules.

1. Introduction

Lung cancer is among the most common cancers and the leading cause of cancer-related death worldwide [1]. Given the advanced diagnostic and surveillance methods, as well as the increasing aging population, there has been a recent increase in the incidence of synchronous multiple primary lung cancer (sMPLC). It is crucial to discriminate sMPLC from primary lung cancer with intrapulmonary metastases (IPM) due to their varying clinical staging, treatment strategies, management, and prognosis. Patients with sMPLC are staged separately and generally treated with curative surgical
resection because of early stage and favorable prognosis while those with IPM in advanced stages receive chemotherapy or radiotherapy with palliative intent [2].

Differential diagnosis between sMPLC and advanced lung cancer is traditionally based on conventional histopathologic features. These include location, morphology, histologic type, time interval, lymphatic invasion, metastases, and clinical manifestation, as described by the Martini and Melamed criteria published in 1975 [3], which was subsequently modified by the American College of Chest Physicians (ACCP) [2]. However, this traditional diagnostic process often involves an overlap in a significant proportion of cases, especially for tumors with a similar morphology or histotype, which impedes the determination of whether they share the same clone origin. Moreover, some patients cannot undergo preoperative histological examination or relative surgery. Further, some tumors cannot be sampled and tested pathologically if the patient has a poor physical condition, including limited cardiopulmonary reserves.

Novel molecular and genomic analyses, including biomarker assessment (driver gene mutations) [4], array comparative genomic hybridization [5], shallow whole-genome sequencing [6], and TP53 mutation analysis [7], can define the between-lesion correlation. These molecular biological techniques allow the detection and analysis of specific molecular markers or mutation sites to determine the heterogeneity of two cancer foci. However, given the substantial misclassification rate, which results from limited sensitivity, stabilization, repeatability, and economic benefits, techniques that could be able to precisely define sMPLC or IPM have not been widely applied in clinic [8].

Preoperative differentiation of primary tumors from metastases is more clinically pivotal than postoperative differentiation. Moreover, preoperative imaging examination plays a significant role. However, there is limited information regarding the imaging and metabolic characteristics of multiple lung cancer nodules [8]. Pretreatment chest high-resolution computed tomography (HRCT) is a conventional and cost-effective means of preliminary diagnosis. Since distinguishing IPM from MLC is empirically based on the morphological pulmonary nodule features, it is difficult to obtain a definitive diagnosis of a primary tumor or metastasis solely based on CT characteristics. Moreover, according to the ACCP clinical practice guidelines, 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) plays a significant role in guiding clinical decisions and is a recommended standard workflow for patients with potentially curable lung cancer [2]. 18F-FDG PET/CT has been extensively used in patients with lung cancer for diagnosis [9], staging [10], prediction (i.e., monitoring therapy response) [11], and prognosis [12]. These mentioned applications indicate that 18F-FDG PET could be used to identify early-stage sMPLC, which involves multiple pulmonary sites. Several heterogeneous methods could be used to determine 18F-FDG uptake. Dynamic PET acquisition, immediately starting from radiotracer injection, measures drug activity change over time. Dynamic PET including multiple frames usually requires long image acquisition time (for 18F-FDG, generally lasting for 60 minutes) and only allows the assessment of one FOV. Generally speaking, the radioactivity concentration of radiotracer in blood and tissue will be changing most rapidly early after injection; therefore, most dynamic PET acquisition has finer time frames at early time points and wider time frames at later time points [13]. On the other hand, static PET acquisition is a common clinical PET acquisition mode. After radiotracer injection for a period of time, when the physiological metabolism or binding in vivo is stable, the multiple-FOV and single frame static emission scan is acquired. For 18F-FDG, static emission scan lasting for 10-15 minutes is usually started at 45-60 minutes postinjection. In routine clinical practice, the standardized uptake value (SUV) based on static PET scanning, which is a simple semi-quantitative index that reflects the metabolic activity of tumor lesions, is widely applied in PET imaging evaluation. SUV is associated with several tumor characteristics, including histopathological subtypes [14]; tumor proliferation [14], differentiation [15], and aggressiveness [16]; and tumor stage, recurrence, and survival [17, 18]. However, the SUV outcome is affected by several factors, including the image acquisition time [19], acquisition mode [20], reconstruction mode [21], serum glucose and insulin levels [22, 23], and positive contrast agent [24]. Theoretically, Patlak graphic analysis based on dynamic PET scanning is the most classically fully quantitative measure of glucose metabolism that involves irreversible trapping. It calculates the 18F-FDG net influx rate constant (i.e., uptake rate constant, K) through linear graphical data fitting [25, 26]. Being a linear kinetic model, Patlak analysis lacks noise amplification and is independent of uptake time and changes in plasma FDG clearance [27, 28].

Since sMPLC with a separate clonal origin often indicates early-stage and less than two-year interval tumorigenesis, we hypothesized that there would be the same SUV or Ki for the initial and second primary lung cancers. Since IPM with an identical clonal origin often indicates late-stage tumorigenesis, we assumed that the SUV or Ki of the primary lung cancer was larger than pulmonary metastases. Moreover, it remains to be assessed whether K calculation through Patlak graphic analysis has values for differentiating sMPLC from IPM in patients with multiple lung cancer nodules since it provides more robust dynamic information and accurate 18F-FDG metabolism quantification.

This study is aimed at assessing the differential diagnostic ability of dynamic 18F-FDG PET scan in patients with lung cancer involving multiple pulmonary sites. This could be able to provide a novel method for sMPLC diagnosis in clinic.

2. Materials and Methods

2.1. Patients. In our center, firstly, all first-visit patients with related symptoms underwent preliminary screening using chest HRCT. Then, other examinations mainly including serologic examination, tumor-associated antigen, brain magnetic resonance imaging, and cervical and abdominal CT scan further clarified the general condition and clinical TNM classification. Fifty-three patients with multiple
pulmonary nodules regardless of extrapulmonary metastases received dynamic 18F-FDG PET scans and had not received any medical treatment before this. After careful preoperative evaluation based on above examination, twenty-seven suitable patients (stage I, stage II, and partial stage IIIA) without medical contraindications received radical surgical resection. Partial inoperable patients (stage IV and partial stage IIIA) were followed by CT-guided percutaneous lung puncture biopsy, bronchoscopic biopsy, or superficial lymph node biopsy mainly based on tumor location. What calls for special attention was that two cases whose Ki/Dmax lower than 0.0001 were excluded considering quantitative inaccuracies due to minima. Finally, this study enrolled forty-three patients with multiple lung cancer nodules (either suspected or proven by biopsy/resection). Based on histopathologic, clinical, radiologic, and genetic features, two experienced oncologists divided those patients into the sMPLC (19 cases) and IMP groups (24 cases) reference to the ACCP evidence-based clinical practice guidelines [2]. That is, the division criteria of sMPLC are (1) same histology, tumor in different lobe as primary, and no N2 and N3 involvement, and no systemic metastases; (2) or different histology, molecular genetic characteristics or arising from a separate focus of carcinoma in situ [2]. The division criteria of IMP are (1) same histology and multiple systemic metastases; (2) or same histology in different lobe and presence of N2 and N3 involvement; (3) or <2-year interval [2]. The inclusion criteria were (1) patients whose preliminary chest HRCT showing multiple pulmonary nodules; (2) patients who performed dynamic 18F-FDG PET/CT for pulmonary nodules; (3) at least two lesions were identified as lung cancers based on histopathologic, clinical, radiologic, and genetic features. The exclusion criteria were (1) no pathological validation; (2) having other diseases that present multiple pulmonary nodules; (3) known history of other malignant diseases; (4) diabetes and/or severe cardiovascular disease. Figure 1 presents the flowchart for case inclusion. Specifically, we only included one lesion pair (two lesions: the largest and second-largest lesion) per patient for simplifying comparisons and calculations, especially for patients with more than two lesions in the lung. Based on the anatomic sites of both lesions, two tumor nodules were subgrouped as follows: (1) tumors confined to the same or different unilateral lung lobes and (2) tumors confined to different bilateral lung lobes. Moreover, the IPM group was classified into 3 subgroups based on the primary tumor size as follows: ≤3 cm subgroup; 3-5 cm subgroup; >5 cm subgroup.

The study was approved by the institutional review board of the Fifth Affiliated Hospital of Sun Yat-sen University (IRB protocol number ZDWH.FZYX.002). All the included patients provided signed informed consent. The clinical trial registration number is NCT03679936. Baseline clinical characteristics, including sex, age, height, weight, smoking history, and tumor characteristics, were obtained from electronic medical records with permission.

2.2. Dynamic PET Data Acquisition and Reconstruction. Dynamic PET/CT scan was performed using 112-ring digital light guide PET/CT (uMI780, United Imaging, China). The patients were fasted for at least 6 h before scanning. The patient was restricted to movement in the scanner to avoid motion artifacts and conducive to subsequent accurate fusion of PET and CT. The scan covered the region between the thoracic inlet and the lower liver margin. Each PET/CT scan began with a transmission CT scan for 5 seconds that was used...
for attenuation correction. Next, an 18F-FDG bolus (range 143–327 MBq) was intravenously injected and a dynamic PET scan was acquired immediately as follows. Dynamic data were collected for 60 min comprising 48 frames with the following dimensions: 18 × 5 s, 6 × 10 s, 5 × 30 s, 5 × 60 s, 8 × 150 s, and 6 × 300 s (Figure 2(a)). The acquired data were corrected for decay, scatter, random, and attenuation; moreover, they were reconstructed using ordered subset expectation maximization.

2.3. PET Data Analysis. Two experienced nuclear medicine physicians analyzed the dynamic 18F-FDG PET/CT images using Carimas 2.10 software (Turku PET center, Finland). Reconstructed PET images were analyzed as follows: (1) definition of volumes of interest (VOIs); (2) obtaining the time-activity curve (TAC) of the left ventricle (i.e., plasma input function) and lung cancer nodules; (3) $K_i$ calculation; (4) SUV$_{max}$ calculation.

First, three-dimensional VOIs were manually drawn over the left ventricle (arterial blood pool) and tumors with a landmark using the Carimas 2.10 software. VOIs were visually localized using CT images. Moreover, the maximum diameters ($D_{max}$) of the two tumors (the largest and second-largest lesion) were measured on multiplanar reconstructed CT images in the lung window via unidimensional measurements based on Response Evaluation Criteria in Solid Tumors 1.0 (RECIST criteria 1.0) [29].

Second, by projecting the VOIs onto the complete dynamic dataset, the Carimas analysis software automatically output relative TAC data of the VOIs. The left ventricle TAC was used for plasma input function, also known as image-derived input function (IDIF).

Third, the TAC of the left ventricle and tumors were used to fit standard Patlak modeling to assess FDG tissue kinetics via the least square regression method using Matlab 2018b (MathWorks Inc., Natick, MA, USA) [25, 26]. Patlak analysis was performed using data obtained between 20 and 60 postinjection minutes (i.e., between frames 38 and 48). The Patlak model for 18F-FDG metabolism in lung cancer (Figure 2(b)) has been previously described in detail [30].

Fourth, the last frame (at 55-60 min postinjection) of the dynamic scans was used for static analysis to obtain the SUV. The SUV$_{max}$ of each pulmonary malignant lesion on PET/CT was extracted from the dynamic data.

2.4. Calculation of Indicators: $\Delta$SUV$_{max}$/D$_{max}$ and $K_i$/D$_{max}$. Based on SUV$_{max}$ measured from 18F-FDG PET, the fitted $K_i$ value obtained through Patlak graphic analysis, and the corresponding maximum diameter ($D_{max}$) of two tumors, the absolute between-tumor difference of SUV$_{max}$/D$_{max}$ and $K_i$/D$_{max}$ ($\Delta$SUV$_{max}$/D$_{max}$; $\Delta$Ki/D$_{max}$) was calculated in both the sMPLC and IPM groups.

2.5. Histopathologic Analysis and Genetic Mutation Analysis. All the punctured tissue and resected specimens were fixed, dehydrated, embedded, sectioned, and stained for microscopic examination. Two experienced pathologists recorded the histopathologic diagnoses and features, including the histotype; lymphatic, nerve, and pleural invasion; extranodal extension; and regional lymph node metastasis.

Gene sequencing of some patients (18 out of 19 in sMPLC group; 20 out of 26 in IPM group) was carried out by the Beijing Genomics Institute. Gene sequencing projects include (1) Oseq TM-T tumor individualized diagnosis and treatment gene detection: 508 gene coding regions and partial intron regions closely related to solid tumors were detected; (2) Oseq TM-ctDNA noninvasive tumor individualized diagnosis and treatment gene detection: 508 gene coding regions and partial intron regions closely related to solid tumors were detected; (3) Oseq TM-T lung cancer individualized diagnosis and treatment gene detection: 20 specific gene mutations (i.e., ALK, EGFR, KRAS, BRAF, ERBB2, RET, MET, ROS1, NRAS, HRAS, DDR2, PIK3CA, AKT1, FBXW7, MAP2K1, FGFR3, NTRK1, KIT, PTEN, and TP53) associated with individualized drug use in lung cancer were detected.
2.6. Statistical Analysis. Between-group differences in baseline characteristics were assessed using an unpaired two-tailed Student’s t-test or chi-square test. Quantitative data were analyzed through descriptive statistics (median (minimum–maximum)), scatter plots, Mann–Whitney test, and Pearson correlation (GraphPad Prism 8 software; two-tailed; 95% confidence intervals). Statistical significance was set at \( p < 0.05 \).

3. Results

3.1. Patient and Tumor Characteristics and Gene Detection Results. There were no differences in the baseline characteristics between the sMPLC and IPM groups. Table 1 summarizes the gender distribution, age, height, body weight, FDG injection dose, and smoking history. IPM diagnoses were
Table 3: Individual results in the sMPLC group.

| Patient no. | Location of tumor 1 | Pathological subtype | 8th TNM stage | $D_{\text{max}-1}$ (cm) | SUV$_{\text{max}-1}$ | $K_{\text{in}}$-$1$ (min$^{-1}$) | Location of tumor 2 | Pathological subtype | 8th TNM stage | $D_{\text{max}-2}$ (cm) | SUV$_{\text{max}-2}$ | $K_{\text{in}}$-$2$ (min$^{-1}$) | $\Delta$SUV$_{\text{max}}/D_{\text{max}}$ | $\Delta$K$_{\text{in}}/D_{\text{max}}$ |
|-------------|---------------------|----------------------|---------------|--------------------------|----------------|-----------------|---------------------|----------------------|---------------|--------------------------|----------------|-----------------|--------------------------|----------------|
| 1           | LUL                 | Papillary            |               | 1.80                     | 3.15           | 0.0201          | RUL                 | Acinar               |               | 1.60                     | 2.72           | 0.0218          | 0.05                      | 0.0025          |
| 2           | LUL                 | Invasive mucinous AC |               | 1.30                     | 1.61           | 0.0192          | LLL                 | Acinar               |               | 1.50                     | 0.27           | 0.0012          | 1.06                      | 0.0140          |
| 3           | LUL                 | Acinar               |               | 1.20                     | 0.32           | 0.0006          | LLL                 | Acinar               |               | 0.40                     | 0.59           | 0.0015          | 1.20                      | 0.0032          |
| 4           | RUL                 | Acinar               |               | 2.20                     | 2.87           | 0.0089          | RML                 | Lepidic              |               | 0.80                     | 0.41           | 0.0009          | 0.80                      | 0.0030          |
| 5           | RUL                 | Acinar               |               | 1.80                     | 1.67           | 0.0068          | RLL                 | Lepidic              |               | 1.00                     | 0.91           | 0.0019          | 0.02                      | 0.0019          |
| 6           | RUL                 | Minimally invasive AC|               | 1.50                     | 0.82           | 0.0006          | LUL                 | Acinar               |               | 2.80                     | 1.59           | 0.0034          | 0.02                      | 0.0008          |
| 7           | LUL                 | Acinar               |               | 5.50                     | 1.47           | 0.0024          | RUL                 | Papillary            |               | 5.20                     | 3.85           | 0.0169          | 0.47                      | 0.0028          |
| 8           | RUL                 | Lepidic              |               | 0.90                     | 0.46           | 0.0007          | RUL                 | Acinar               |               | 0.90                     | 0.89           | 0.0014          | 0.48                      | 0.0007          |
| 9           | RUL                 | Papillary            |               | 1.20                     | 0.62           | 0.0049          | RLL                 | Acinar               |               | 0.30                     | 0.80           | 0.0006          | 2.16                      | 0.0022          |
| 10          | RUL                 | Acinar               |               | 0.70                     | 0.66           | 0.0011          | RUL                 | Minimally invasive AC|               | 0.30                     | 0.69           | 0.0004          | 1.37                      | 0.0004          |
| 11          | RUL                 | Acinar               |               | 3.00                     | 8.76           | 0.0312          | RLL                 | —                    |               | 1.00                     | 0.84           | 0.0012          | 2.08                      | 0.0093          |
| 12          | RUL                 | Acinar               |               | 1.20                     | 0.62           | 0.0006          | RLL                 | Papillary            |               | 0.60                     | 0.88           | 0.0038          | 0.96                      | 0.0058          |
| 13          | RUL                 | Minimally invasive AC|               | 0.60                     | 0.95           | 0.0004          | RLL                 | Acinar               |               | 1.30                     | 0.56           | 0.0004          | 1.16                      | 0.0004          |
| 14          | LLL                 | Acinar               |               | 2.00                     | 4.10           | 0.0206          | RML                 | —                    |               | 0.60                     | 0.37           | 0.0006          | 1.43                      | 0.0094          |
| 15          | RLL                 | Acinar               |               | 3.10                     | 1.65           | 0.0071          | RUL                 | —                    |               | 0.50                     | 0.79           | 0.0019          | 1.05                      | 0.0014          |
| 16          | RML                 | Acinar               |               | 2.00                     | 0.48           | 0.0014          | RLL                 | Acinar               |               | 2.90                     | 0.95           | 0.0055          | 0.09                      | 0.0012          |
| 17          | RUL                 | —                    |               | 2.60                     | 3.25           | 0.0120          | RLL                 | AC                   |               | 4.60                     | 4.45           | 0.0224          | 0.28                      | 0.0003          |
| 18          | RUL                 | Acinar               |               | 2.00                     | 0.93           | 0.0028          | RLL                 | Minimally invasive AC|               | 0.50                     | 0.60           | 0.0015          | 0.73                      | 0.0017          |
| 19          | LUL                 | —                    |               | 0.50                     | 0.42           | 0.0005          | RLL                 | Acinar               |               | 0.90                     | 0.55           | 0.0003          | 0.22                      | 0.0007          |

Median (min–max) 0.96 (0.02-2.16) 0.0019 (0.0003-0.0140)

*Specifically, tumor 1 and tumor 2 in patient no. 16 have the same pathological subtype, but the different gene mutation. sMPLC: synchronous multiple primary lung cancer; $D_{\text{max}-1}$: largest diameter of tumor 1; $D_{\text{max}-2}$: largest diameter of tumor 2; $K_{\text{in}}$: influx rate constant; SUV$_{\text{max}-1}$: maximum standardized uptake value of tumor 1; SUV$_{\text{max}-2}$: SUV$_{\text{max}}$ of tumor 2; $\Delta$SUV$_{\text{max}}/D_{\text{max}}$: absolute difference between SUV$_{\text{max}-1}/D_{\text{max}-1}$ and SUV$_{\text{max}-2}/D_{\text{max}-2}$; $\Delta K_{\text{in}}/D_{\text{max}}$: absolute difference between $K_{\text{in}-1}/D_{\text{max}-1}$ and $K_{\text{in}-2}/D_{\text{max}-2}$; RUL: right upper lobe; RML: right middle lobe; RLL: right lower lobe; LUL: left upper lobe; LLL: left lower lobe; AC: adenocarcinoma. Blank represents not available or there is no corresponding detection.
| Patient no. | Location of primary tumor | Pathological type | 8th TNM stage | $D_{\text{max-\text{pt}}}$ (cm) | $\text{SUV}_{\text{max-\text{pt}}}$ (min$^{-1}$) | $K_{\text{f-\text{pt}}}$ (min$^{-1}$) | Location of metastatic tumor | $D_{\text{max-mt}}$ (cm) | $\text{SUV}_{\text{max-mt}}$ (min$^{-1}$) | $K_{\text{f-mt}}$ (min$^{-1}$) | $\Delta \text{SUV}_{\text{max}}/D_{\text{max}}$ | $\Delta K_{\text{f}}/D_{\text{max}}$ |
|-------------|-------------------------|------------------|----------------|-----------------------------|---------------------------------|---------------------------------|-------------------------|-----------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| 1           | RCLC                    | AC               | cT2bN3M1c, IVB | 4.80                        | 7.70                            | 0.0375                          | LUL                     | 0.60                        | 1.05                            | 0.0036                          | 0.15                            | 0.0019                          |
| 2           | LUL                     | AC               | cT4N2M1c, IVB | 1.90                        | 8.71                            | 0.0687                          | LLL                     | 0.70                        | 5.24                            | 0.0339                          | 2.91                            | 0.0122                          |
| 3           | RLL                     | AC               | cT1cN3M1c, IVB | 2.30                        | 16.06                           | 0.0620                          | LUL                     | 0.30                        | 1.00                            | 0.0012                          | 3.65                            | 0.0228                          |
| 4           | LLL                     | AC               | cT3N2M1b, IVA  | 6.20                        | 14.04                           | 0.0612                          | LLL                     | 1.00                        | 3.29                            | 0.0212                          | 1.02                            | 0.0113                          |
| 5           | LUL                     | AC               | cT1bN1M1c, IVB | 1.60                        | 8.84                            | 0.0489                          | RML                     | 0.60                        | 0.48                            | 0.0007                          | 4.72                            | 0.0294                          |
| 6           | LUL                     | AC               | PT3N2M1b, IVA  | 2.90                        | 6.46                            | 0.0344                          | LUL                     | 1.50                        | 1.20                            | 0.0020                          | 1.43                            | 0.0105                          |
| 7           | RCLC                    | AC               | PT2aN3M1c, IVB | 3.80                        | 5.05                            | 0.0263                          | RLL                     | 4.00                        | 5.52                            | 0.0316                          | 0.05                            | 0.0010                          |
| 8           | LLL                     | NSCLC            | cT4N3M1c, IVB  | 4.80                        | 8.68                            | 0.0458                          | LUL                     | 1.30                        | 4.51                            | 0.0201                          | 1.66                            | 0.0060                          |
| 9           | LUL                     | Poorly differentiated carcinoma | cT4N3M1a, IVA | 7.60                        | 11.11                           | 0.0556                          | RUL                     | 2.50                        | 9.47                            | 0.0411                          | 2.33                            | 0.0091                          |
| 10          | LLL                     | AC               | cT4N3M1c, IVB  | 5.80                        | 8.06                            | 0.0611                          | LUL                     | 0.40                        | 0.61                            | 0.0014                          | 0.13                            | 0.0069                          |
| 11          | LCLC                    | AC               | cT4N2M1a, IVA  | 8.80                        | 7.89                            | 0.0471                          | LLL                     | 4.80                        | 5.80                            | 0.0341                          | 0.31                            | 0.0018                          |
| 12          | RCLC                    | SCC              | cT2aN3M1b, IVA  | 3.90                        | 7.26                            | 0.0453                          | RUL                     | 1.40                        | 0.96                            | 0.0039                          | 1.17                            | 0.0088                          |
| 13          | RLL                     | Invasive AC, acinar | PT1cN3M1c, IVB | 3.00                        | 10.22                           | 0.0499                          | LUL                     | 1.80                        | 0.43                            | 0.0002                          | 3.17                            | 0.0165                          |
| 14          | RUL                     | Lung cancer      | cT3N3M1c, IVB  | 4.10                        | 13.85                           | 0.0551                          | RUL                     | 0.50                        | 0.60                            | 0.0007                          | 2.17                            | 0.0120                          |
| 15          | RUL                     | Invasive AC, papillary | PT4N2M1a, IVA | 2.20                        | 4.98                            | 0.0289                          | RLL                     | 0.50                        | 0.75                            | 0.0009                          | 0.77                            | 0.0113                          |
| 16          | RML                     | AC               | PT4N2M1b, IVA  | 3.30                        | 9.49                            | 0.0423                          | RLL                     | 0.40                        | 0.64                            | 0.0003                          | 1.27                            | 0.0122                          |
| 17          | RCLC                    | AC               | PT2bN1M1a, IVA  | 4.40                        | 13.69                           | 0.0756                          | LUL                     | 1.10                        | 2.28                            | 0.0078                          | 1.04                            | 0.0099                          |
| 18          | RML                     | SCC              | cT4N3M1a, IVA  | 4.90                        | 9.79                            | 0.0547                          | RLL                     | 0.50                        | 0.37                            | 0.0011                          | 1.26                            | 0.0090                          |
| 19          | RML                     | AC               | cT4N3M1a, IVA  | 6.00                        | 6.97                            | 0.0381                          | RUL                     | 1.40                        | 1.59                            | 0.0065                          | 0.03                            | 0.0017                          |
| Patient no. | Location of primary tumor | Pathological type | 8th TNM stage | Location of metastatic tumor | \( D_{\text{max-pt}} \) (cm) | \( D_{\text{max-mt}} \) (cm) | \( \text{SUV}_{\text{max-pt}} \) | \( \text{SUV}_{\text{max-mt}} \) | \( K_{\text{i-pt}} \) (min\(^{-1}\)) | \( K_{\text{i-mt}} \) (min\(^{-1}\)) | \( \Delta \text{SUV}_{\text{max}}/D_{\text{max}} \) | \( \Delta K_{\text{i}}/D_{\text{max}} \) |
|-------------|--------------------------|------------------|----------------|---------------------------|-----------------|-----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| 20          | LLL                      | SCC              | cT4N3M1c, IVB  | cT3N1M0, IIIA             | 5.00            | 1.50            | 9.85           | 6.71           | 0.0535         | 0.0359         | 2.50           | 0.0132         |
| 21          | RLL                      | Invasive AC, acinar | pT4N0M0, IIIA | RUL                       | 1.80            | 0.30            | 1.33           | 0.43           | 0.0042         | 0.0006         | 0.68           | 0.0004         |
| 22          | LUL                      | Invasive AC, acinar | pT4N2M0, IIIB | LUL                       | 2.80            | 0.40            | 9.26           | 0.14           | 0.0497         | 0.0002         | 2.96           | 0.0174         |
| 23          | RLL                      | AC               | cT4N2M0, IIIB | RUL                       | 1.80            | 0.50            | 6.28           | 0.59           | 0.0327         | 0.0010         | 2.31           | 0.0161         |
| 24          | RUL                      | AC               | cT1cN3M1c, IVB | LUL                       | 1.60            | 2.50            | 6.35           | 6.88           | 0.0413         | 0.0456         | 1.22           | 0.0076         |

Median (min–max)

\[
\text{Median (min–max) } 1.27 \quad (0.03-4.72) \\
0.0102 \quad (0.0004-0.0294)
\]

IPM: intrapulmonary metastases; \( D_{\text{max-pt}} \): largest diameter of primary tumor; \( D_{\text{max-mt}} \): largest diameter of metastatic tumor; \( K_{\text{i}} \): influx rate constant; \( \text{SUV}_{\text{max}} \): maximum standardized uptake value; \( \text{SUV}_{\text{max-pt}} \): \( \text{SUV}_{\text{max}} \) of primary tumor; \( \text{SUV}_{\text{max-mt}} \): \( \text{SUV}_{\text{max}} \) of metastatic tumor; \( K_{\text{i-pt}} \): \( K_{\text{i}} \) of primary tumor; \( K_{\text{i-mt}} \): \( K_{\text{i}} \) of metastatic tumor; \( \Delta \text{SUV}_{\text{max}}/D_{\text{max}} \): absolute difference between \( \text{SUV}_{\text{max-pt}}/D_{\text{max-pt}} \) and \( \text{SUV}_{\text{max-mt}}/D_{\text{max-mt}} \); \( \Delta K_{\text{i}}/D_{\text{max}} \): absolute difference between \( K_{\text{i-pt}}/D_{\text{max-pt}} \) and \( K_{\text{i-mt}}/D_{\text{max-mt}} \); RUL: right upper lobe; RML: right middle lobe; RLL: right lower lobe; LUL: left upper lobe; LLL: left lower lobe; RCLC: right central lung cancer; LCLC: left central lung cancer; AC: adenocarcinoma; SCC: squamous cell carcinoma; NSCLC: non-small cell lung cancer.
mainly based on radiologic and clinical patterns although the primary tumor was pathologically confirmed. sMPLC diagnoses were primarily based on histopathologic features. In both the sMPLC and IPM groups, the most commonly diagnosed tumor was adenocarcinoma with a majority being unilateral (68% and 71%, respectively). Table 1 presents the tumor characteristics. Supplementary Tables S1 and S2, respectively, show the detailed gene mutation detection information of the sMPLC and IPM groups, mainly including sample type, tumor mutation burden, microsatellite instability, and mutations detected. EGFR mutations were the most common mutations whether in the sMPLC group or in the IPM group. Particularly, in the sMPLC group, almost two primary tumors were tested for mutation detection because of high resection rate and diagnosis requirement; however,
Figure 4: Continued.
Figure 4: Continued.
only primary tumors were tested for mutation detection in the IPM group because almost only one lesion was resected or biopsied (Supplementary Tables S1 and S2).

3.2. sMPLC vs. IPM: Absolute Differences of \( \frac{SUV_{\text{max}}}{D_{\text{max}}} \) or \( \frac{K_i}{D_{\text{max}}} \). There was no significant difference in \( \Delta SUV_{\text{max}}/D_{\text{max}} \) between the IPM and sMPLC groups (1.27 (0.03–4.72) vs. 0.96 (0.02–2.16), \( p > 0.05 \)). Contrastingly, \( \Delta K_i/D_{\text{max}} \) was significantly higher in the IPM group than in the sMPLC group (0.0102 (0.0004-0.0294) vs. 0.0019 (0.0003-0.0140), \( p < 0.001 \) (Tables 2–4, Figures 3(a) and 3(b)). Supplementary Table S3 shows the comparison of \( \Delta SUV_{\text{max}}/D_{\text{max}} \) and \( \Delta K_i/D_{\text{max}} \) between different age groups and no significant difference was found within their respective groups. Considering a small clinical sample size, internal validation by Bootstrap method by SPSS 25.0 further validated the reproducibility. When performing bootstrapping based on 1000 bootstrap samples, the difference was still more significant in \( \Delta K_i/D_{\text{max}} \) (\( p = 0.003 \)) than in \( \Delta SUV_{\text{max}}/D_{\text{max}} \) (\( p = 0.031 \)) between two groups (Supplementary Table S4). However, we did not conduct external validation because of limited included cases at present. There was a good correlation (Pearson \( r = 0.91 \), 95% CI: 0.79-0.96, \( p < 0.0001 \), Figure 3(d)) between \( \Delta SUV_{\text{max}}/D_{\text{max}} \) and \( \Delta K_i/D_{\text{max}} \) in the IPM group but not the sMPLC group (Pearson \( r = 0.45 \), \( p > 0.05 \), Figure 3(c)). Figures 3(a)–3(d) present the data distribution and correlation in both groups while Figure 4 shows sMPLC and IPM examples. Tables 3 and 4 independently present individual results of each case in the sMPLC group and the IPM group including location of tumor, pathological subtype/type, 8th TNM stage, \( D_{\text{max}} \) and \( \frac{SUV_{\text{max}}}{D_{\text{max}}} \). Since there was a good correlation between \( \Delta SUV_{\text{max}}/D_{\text{max}} \) and \( \Delta K_i/D_{\text{max}} \), the area under the curve (AUC) was 0.80 (95% CI: 0.67–0.93, \( p < 0.001 \)) for distinguishing sMPLC from IPM (Figure 3(f)), which suggested that \( \frac{\Delta K_i}{D_{\text{max}}} \) had a moderately high diagnostic value. The left upper corner (\( \Delta K_i/D_{\text{max}} = 0.0059 \)) of the ROC curve with the maximal Youden index was chosen as the optimal cut-off point, which had a sensitivity and specificity of 79% and 75%, respectively. The corresponding false-positive and false-negative rate was 25% and 21%.

3.3. Receiver Operating Characteristic (ROC) Curve Analysis. ROC curve analysis was used to determine the diagnostic accuracy of \( \Delta SUV_{\text{max}}/D_{\text{max}} \) and \( \Delta K_i/D_{\text{max}} \). For \( \Delta SUV_{\text{max}}/D_{\text{max}} \), ROC curve (AUC = 0.66, Figure 3(e)) indicated low diagnostic value. For \( \Delta K_i/D_{\text{max}} \) the area under the curve (AUC) was 0.80 (95% CI: 0.67–0.93, \( p < 0.001 \)) for distinguishing sMPLC from IPM (Figure 3(f)), which suggested that \( \frac{\Delta K_i}{D_{\text{max}}} \) had a moderately high diagnostic value. The left upper corner (\( \Delta K_i/D_{\text{max}} = 0.0059 \)) of the ROC curve with the maximal Youden index was chosen as the optimal cut-off point, which had a sensitivity and specificity of 79% and 75%, respectively. The corresponding false-positive and false-negative rate was 25% and 21%.

3.4. Unilateral sMPLC vs. Bilateral sMPLC. The lesion location has been reported to contribute to the over survival
Therefore, we compared the results between unilateral and bilateral sMPLC. The bilateral sMPLC group had a slightly higher $\Delta K_i/D_{\text{max}}$. However, there was no significant difference between unilateral and bilateral sMPLC with respect to $\Delta \text{SUV}_{\text{max}}/D_{\text{max}}$ and $\Delta K_i/D_{\text{max}}$ (Supplementary Figures S1(a) and S1(b)).

**Table 5: Diagnostic results based on CT characteristics.**

| Patient no. | Tumor 1     | Tumor 2     | $\Delta \text{SUV}_{\text{max}}/D_{\text{max}}$ | $\Delta K_i/D_{\text{max}}$ |
|------------|-------------|-------------|-----------------------------------------------|-----------------------------|
| sMPLC group|             |             |                                               |                             |
| 1          | Primary     | Primary     | 0.05                                          | 0.0025                      |
| 2          | Primary     | Unsure      | 1.06                                          | 0.0140                      |
| 3          | Unsure      | Unsure      | 1.20                                          | 0.0032                      |
| 4          | Primary     | Unsure      | 0.80                                          | 0.0030                      |
| 5          | Primary     | Primary     | 0.02                                          | 0.0019                      |
| 6          | Primary     | Primary     | 0.02                                          | 0.0008                      |
| 7          | Primary     | Primary     | 0.47                                          | 0.0028                      |
| 8          | Unsure      | Unsure      | 0.48                                          | 0.0007                      |
| 9          | Primary     | Unsure      | 2.16                                          | 0.0022                      |
| 10         | Primary     | Unsure      | 1.37                                          | 0.0004                      |
| 11         | Primary     | Primary     | 2.08                                          | 0.0093                      |
| 12         | Primary     | Unsure      | 0.96                                          | 0.0058                      |
| 13         | Unsure      | Primary     | 1.16                                          | 0.0004                      |
| 14         | Primary     | Primary     | 1.43                                          | 0.0094                      |
| 15         | Primary     | Primary     | 1.05                                          | 0.0014                      |
| 16         | Primary     | Primary     | 0.09                                          | 0.0012                      |
| 17         | Primary     | Primary     | 0.28                                          | 0.0003                      |
| 18         | Primary     | Unsure      | 0.73                                          | 0.0017                      |
| 19         | Primary     | Primary     | 0.22                                          | 0.0007                      |
| 20         | Primary     | Metastasis  | 0.15                                          | 0.0019                      |
| 21         | Primary     | Metastasis  | 2.91                                          | 0.0122                      |
| 22         | Primary     | Metastasis  | 3.65                                          | 0.0228                      |
| 23         | Primary     | Metastasis  | 1.02                                          | 0.0113                      |
| 24         | Primary     | Metastasis  | 4.72                                          | 0.0294                      |
| 25         | Primary     | Metastasis  | 1.43                                          | 0.0105                      |
| 26         | Primary     | Metastasis  | 1.43                                          | 0.0010                      |
| 27         | Primary     | Metastasis  | 1.66                                          | 0.0060                      |
| 28         | Primary     | Metastasis  | 2.33                                          | 0.0091                      |
| 29         | Primary     | Metastasis  | 0.13                                          | 0.0069                      |
| 30         | Primary     | Metastasis  | 0.31                                          | 0.0018                      |
| 31         | Primary     | Metastasis  | 1.17                                          | 0.0088                      |
| 32         | Primary     | Metastasis  | 3.17                                          | 0.0165                      |
| 33         | Primary     | Metastasis  | 2.17                                          | 0.0120                      |
| 34         | Primary     | Unsure      | 0.77                                          | 0.0113                      |
| 35         | Primary     | Unsure      | 1.27                                          | 0.0122                      |
| 36         | Primary     | Primary     | 1.04                                          | 0.0099                      |
| 37         | Primary     | Metastasis  | 1.26                                          | 0.0090                      |
| 38         | Primary     | Metastasis  | 0.03                                          | 0.0017                      |
| 39         | Primary     | Metastasis  | 2.50                                          | 0.0132                      |
| 40         | Primary     | Unsure      | 0.68                                          | 0.0004                      |
| 41         | Primary     | Unsure      | 2.96                                          | 0.0174                      |
| 42         | Primary     | Metastasis  | 2.31                                          | 0.0161                      |
| 43         | Primary     | Metastasis  | 1.22                                          | 0.0076                      |

"Primary" represents that tumors were considered as primary tumors. "Metastasis" represents that tumors were considered as metastatic tumors. "Unsure" represents that no definite diagnosis could be made based on CT characteristics.

(OS) of MPLC [31, 32]; therefore, we compared the results between unilateral and bilateral sMPLC. The bilateral sMPLC group had a slightly higher $\Delta K_i/D_{\text{max}}$. However, there was no significant difference between unilateral and bilateral sMPLC with respect to $\Delta \text{SUV}_{\text{max}}/D_{\text{max}}$ and $\Delta K_i/D_{\text{max}}$ (Supplementary Figures S1(a) and S1(b)).
3.5. Unilateral IPM vs. Bilateral IPM. According to the 8th Edition Lung Cancer Stage Classification, unilateral and bilateral IPM could have different T and M categories, which indicates different stages and OS [33]. Therefore, we compared differences in the indicators between unilateral and bilateral IPM. The bilateral IPM group had a slightly higher ΔSU \( V_{\text{max}}/D_{\text{max}} \). However, there was no significant difference between unilateral and bilateral sMPLC in terms of ΔSU \( V_{\text{max}}/D_{\text{max}} \) and ΔKi/Dmax (Supplementary Figures S1(c) and S1(d)).

3.6. IPM Subgroup Comparisons Based on Primary Tumor Size (≤3 cm vs. 3-5 cm vs. >5 cm). Size plays a critical role in defining the T category as indicated by the proposed size cutpoints of the 8th edition Lung Cancer Stage Classification [34]. We compared differences in the indicators among three IPM subgroups (≤3 cm vs. 3-5 cm vs. >5 cm). Nevertheless, there was no significant among-group difference in ΔSU \( V_{\text{max}}/D_{\text{max}} \) and ΔKi/Dmax (Supplementary Figure S2).

3.7. Diagnostic Results Based on CT Characteristics. Table 5 summarizes the diagnostic results of at least two experienced radiologists based on CT characteristics in the sMPLC group and the IPM group. Based on CT characteristics, 26 out of 43 cases were diagnosed correctly. Based on the optimal cut-off value of ΔKi/Dmax = 0.0059, 35 out of 43 cases were diagnosed correctly. Therefore, ΔKi/Dmax performed better than experienced CT diagnosis in differentiating sMPLC from IPM.

4. Discussion

To our knowledge, this was the first study on the application of dynamic \(^{18}\text{F}-\text{FDG}\) PET to discriminate between tumors with common (i.e., IPM) and separate (i.e., sMPLC) lineages. Previous PET studies have predominantly focused on static imaging. Our findings indicated that dynamic \(^{18}\text{F}-\text{FDG}\) PET could be able to provide more detailed parameters for sMPLC identification.

The Martini and Melamed criteria are currently the most widely accepted; however, there remains no standard and uniform clinical guidelines for MPLC. There is no consensus among major lung cancer research institutes regarding MPLC classification. It is difficult to discriminate sMPLC from IPM without a lung, lymph node biopsy, or surgical procedure, which is important since the two conditions have significantly different therapeutic regimens and prognosis. Previous studies have reported that the OS of patients with MPLC was significantly better than those with metastatic tumors [31, 35]. Patients with MPLC are generally treated with curative surgical treatment while those in advanced stages receive chemotherapy or radiotherapy with palliative intent [2].

In routine clinical settings, preoperative differentiation of primary tumors from metastases is more critical than postoperative differentiation. Moreover, preoperative imaging examination plays a crucial role. It is recommended that patients with multiple pulmonary nodules undergo PET scans for careful systemic assessment based on the ACCP guidelines [2]. There is limited information regarding the imaging and metabolic characteristics of multiple lung cancer nodules [8]. Moreover, there have been few studies on the value of preoperative imaging for distinguishing MPLC from IPM in patients with multiple lung cancers [36].

Several case reports have reported incidental detection of sMPLC using \(^{18}\text{F}-\text{FDG}\) PET [37–40]. Contrastingly, there have been few studies indicating that \(^{18}\text{F}-\text{FDG}\) PET could be able to locate the clonal origin of synchronous multiple tumors [41–43]. Dijkman et al. reported that the relative between-tumor difference in SUV – ΔSUV%/((bigger SUV – smaller SUV)/bigger SUV) could distinguish advanced disease from second primary tumors in patients with synchronous pulmonary lesions [41]. In this previous study, the second primary tumor group included initial primary cancers originating from the lung or other organs with second primary lung cancer. The metastatic disease group (control) included primary lung cancers with intrapulmonary metastases and extrapulmonary cancers with pulmonary metastases. Therefore, their findings reflect the differential diagnostic ability of ΔSUV% from a wider scope that includes cancers originating from the lungs or other organs. Furthermore, Pang et al. reported that \(^{18}\text{F}-\text{FDG}\) PET/CT could diagnose synchronous multiple primary cancers; further, ΔSUV% could identify the different pathological origins of synchronous cancers. Consistent with the findings by Dijkman et al., Pang et al. assessed synchronous multiple primary cancers, including primary lung cancers and extrapulmonary cancers [39]. Kosaka et al. assessed 75 cases of lung cancers with 296 metastases and reported that the SUV ratio (i.e., metastatic SUV to primary SUV) could differentiate primary lung cancer from metastasis [42]. However, most of the metastatic lesions were not pathologically confirmed and they only assessed lung cancers with metastases in the following sites: lymph nodes, bones, liver, pleura/lung, adrenal, kidney, and small intestine. Since this study did not involve a control group, its conclusions were empirical and probabilistic.

Similar to our study, Liu et al. only included patients with both cancers located in the lung and reported significant differences in the SUVmax ratio (bigger SUVmax/smaller SUVmax) between sMPLC and IPM. This indicated that the between-tumor SUVmax ratio could differentiate sMPLC from IPM [43]. In our study, we did not find a significant between-group difference in the SUVmax ratio and \( K'_p \) ratio. These inconsistent findings could be attributed to differences in the sample size and study population, as well as inclusion and exclusion criteria.

Both Dijkman et al. and Liu et al. suggested that the SUV of tumors with a common lineage were more consistent than those with separate lineage [41, 43]. Moreover, they reported that related indicators (e.g., ΔSUV% and SUVmax ratio) were significantly higher in the sMPLC group than in the IPM group. Inconsistent with these previous findings, we found that ΔSU \( V_{\text{max}}/D_{\text{max}} \) was numerically, but not significantly, larger in the IPM group than in the sMPLC group. Nevertheless, ΔKi/Dmax was significantly larger in the IPM group than in the sMPLC group.
In our study, there was a good correlation between $\Delta \text{SUV}_{\text{max}}/D_{\text{max}}$ and $\Delta K_i/D_{\text{max}}$ in the IPM group, but not in the sMPLC group, which could be attributed to the identical and separate clone origin, respectively. The moderately high accuracy of $\Delta K_i/D_{\text{max}}$ indicated by the AUC provided further evidence for the application of dynamic $^{18}$F-FDG PET as an auxiliary modality for discriminating sMPLC from IPM. We considered the size and SUV$_{\text{max}}$ of the tumor as indexes since related studies have reported that these indexes can predict postoperative outcomes in patients with sMPLC [44]. Previous studies have reported adenocarcinoma as the major histopathological type in patients with sMPLC [45]. Moreover, the histologic type of initial and second primary lung cancers has been reported to be mostly similar [2, 35], which is consistent with our findings. Jiang et al. reported no significant OS differences between unilateral and bilateral MPLC [31]. Contrastingly, Troussel et al. reported that patients with bilateral MPLC had a better outcome than those with unilateral MPLC. Further, in patients with unilateral MPLC, lesions within the same lobe have been associated with better survival compared to those in different lobes [32]. Consequently, we assessed differences between unilateral and bilateral sMPLC. However, there was no significant between-group difference in $\Delta$SUV$_{\text{max}}/D_{\text{max}}$ and $\Delta K_i/D_{\text{max}}$. But the bilateral sMPLC group had a slightly higher $\Delta K_i/D_{\text{max}}$, which may indicate a later disease stage.

According to the 8th Edition Lung Cancer Stage Classification [46], a separate T, N, M category should be designated to each tumor for second primary lung cancer. However, for patients with IPM, tumor nodules located in the same and different lobes of the unilateral lung and in the bilateral lung are staged as T3, T4, and M1a, respectively. As a result, unilateral IPM and bilateral IPM have different T and M categories, which is indicative of different stages. Regarding the site of the separate tumor nodule relative to the primary tumor in clinically staged patients, tumors in the same lobe are associated with a superior OS than those in different ipsilateral lobes. Moreover, the tumors with different contralateral lobes were associated with the worst OS [33]. Consequently, we determined differences in the indicators between unilateral IPM and bilateral IPM. Although there was no significant difference, the bilateral IPM group had a slightly higher $\Delta$SUV$_{\text{max}}/D_{\text{max}}$ than the unilateral IPM group, which was indicative of a later disease stage.

Size plays a significant role in defining the T category as shown by the proposed size cut-points of the 8th Edition Lung Cancer Stage Classification. Survival analysis with 1 cm increments in tumor size showed that survival progressively decreased for each 1 cm cut-point [34]. The 3 cm, 5 cm, and 7 cm cut-points significantly separate T1, T2, T3, and T4, respectively, when only the primary tumor size is taken into consideration [46]. We did not observe a significant difference in $\Delta$SUV$_{\text{max}}/D_{\text{max}}$ and $\Delta K_i/D_{\text{max}}$ among the three IPM subgroups ($\leq$3 cm vs. 3-5 cm vs. $>$5 cm) based on the primary tumor size.

We observed that $\Delta K_i/D_{\text{max}}$ was a sensitive indicator, which could be explained by three main differences between SUV and Patlak $K_i$. First, SUV measures phosphorylated and unphosphorylated FDG in the tumor while Patlak $K_i$ only considers phosphorylated FDG [47]. Second, SUV is strongly dependent on uptake time and changes in plasma FDG clearance while Patlak $K_i$ is independent of both [27, 47]. Third, Patlak $K_i$ employs the integral under the plasma input function for normalization while SUV approximates this integral using the injected dose divided by the body weight [47]. Consequently, SUV and Patlak $K_i$ measure different quantities with the later providing more robust dynamic information and more accurate $^{18}$F-FDG metabolism quantification. FDG metabolism quantification via Patlak analysis has several advantages over using SUV since it involves linear modeling without noise amplification and is independent of the uptake time and changes in plasma FDG clearance [27, 28]. However, for calculating fitted $K_i$ by dynamic mathematical model, dynamic scan (tissue TAC) and arterial blood sampling (arterial blood TAC, but substitutable with IDIF) are required, which is unsuitable in clinical settings. The reason why it is difficult to perform dynamic PET/CT acquisition in the current clinical practice mainly include the following. (1) Long acquisition time and tedious acquisition process may not be practical for clinical centers with a large number of patients to be examined because of low working efficiency [13]. (2) Many patients, particularly those with advanced cancers, could not be able to tolerate long acquisition time because the patient is restricted to movement in the scanner and will feel uncomfortable [13]. (3) The conventional and common PET scanner only has the limited axial field of view of about 15-25 cm, confining dynamic PET to a single bed position or one FOV [48]. On the other hand, static analysis only requires a 10-15 min static scan at a fixed time, which is usually 45-60 min after injection. In daily clinic, a single frame static image may provide enough desired information within acceptable error limits in most instances [13]. The selection of ideal analytical method should consider an optimal trade-off between quantitative accuracy and clinical convenience [13, 28]. Therefore, SUV is recommended when prioritizing clinical applicability and simplicity. Nevertheless, with the gradual development of the total-body PET scanner equipped with a long axial field of view of 194 cm, short-time dynamic total-body PET imaging with favorable spatial and temporal resolution and signal-to-noise ratio will make dynamic PET imaging more acceptable and popular in clinical application [48, 49].

This study has several limitations. Firstly, we employed a small sample size (43 cases); therefore, the results are preliminary and exploratory. Second, most of the cases with metastatic disease were diagnosed without histopathological confirmation based on typical clinical and radiological features, although the primary tumor was pathologically confirmed. Third, partial tumors were <1 cm with low SUV, which could have resulted in SUV biases due to the partial volume effect and statistical noise [50]. Fourth, for the optimal cut-off value of $\Delta K_i/D_{\text{max}} = 0.0059$ with a sensitivity of 79% and specificity of 75%, the corresponding false-positive and false-negative rate was 25% and 21% in this study. For this study, the diagnostic ability of a single indicator ($\Delta$SUV$_{\text{max}}/D_{\text{max}}$ or $\Delta K_i/D_{\text{max}}$) was not particularly high, but $\Delta K_i/D_{\text{max}}$ performed better. Meanwhile, further external validation is needed.
5. Conclusions

Our findings indicated that dynamic $^{18}$F-FDG PET/CT could be a useful tool for distinguishing sMPLC from IPM, complemented by histopathologic, clinical, and genetic evaluation, especially during preoperative assessment, which is mainly dependent on clinical and imaging characteristics. $K_r$ calculation based on Patlak graphic analysis could be more sensitive for distinguishing metastatic disease from sMPLC in patients with multiple lung cancer nodules. There is a need for further studies to confirm the consistency of our findings.

Data Availability

The data presented in this study are available on reasonable request from the corresponding author. The data are not publicly available due to privacy or ethical issues.

Ethical Approval

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the Fifth Affiliated Hospital of Sun Yat-sen University (IRB protocol number ZDWY.FZYX.002).

Consent

Informed consent was obtained from all subjects involved in the study.

Conflicts of Interest

The authors declare no conflict of interest.

Authors’ Contributions

H.J.J. and Q.D.C. were responsible for conceptualization; W.Z.L. and M.Y. were responsible for methodology; S.Y. and L.B. were responsible for software; X.F.P. and X.J.W. were responsible for formal analysis; X.H.H. and H.C.Z. were responsible for investigation; Q.D.C., Y.W., and Z.L. were responsible for resources; J.Z.X., X.H.H., H.C.Z., and X.J.W. were responsible for data curation; W.Z.L. and M.Y. were responsible for writing—original draft preparation; H.J.J. and Q.D.C. were responsible for writing—review and editing; W.Z.L. and M.Y. were responsible for visualization; H.J.J. was responsible for supervision; H.J.J. and Q.D.C. were responsible for project administration; H.J.J. and H.S. were responsible for funding acquisition. All authors have read and agreed to the published version of the manuscript. Weize Lv and Min Yang are equally contributed to this study as the first author. HongJun Jin and Qingdong Cao are equally contributed to this study as the first author. Hongjun Jin and Qingdong Cao are equally contributed to this study as the first author. Hongjun Jin and Qingdong Cao are equally contributed to this study as the first author.

Acknowledgments

The authors would like to thank the patients who participated in the study. Moreover, the authors appreciate Ms. Ping Jiang, Ms. Xiaojuan Jia, Mr. Wenhua Xu, and Mr. Fanwei Zhang from the Department of Nuclear Medicine, the Fifth Affiliated Hospital of Sun Yat-sen University, for their technical supports. Thanks are due to Prof. Chunlei Han for his kind help in model fitting from Turku PET Centre, Finland. This research was funded by the National Key R&D Program of China (2018YFC0910600), the National Natural Science Foundation of China (81871382 and 82150610508), grants from the Guangdong Science and Technology Department to the Guangdong Provincial Key Laboratory of Biomedical Imaging (2018B030322006), and Starting Fund (310103050303-220904094238) from the Fifth Affiliated Hospital, Sun Yat-sen University.

Supplementary Materials

Figure S1: there was no significant difference in $\Delta$SUV$_{max}$/$D_{max}$ and $\Delta K_r$/$D_{max}$ between the unilateral and bilateral sMPLC group (a, b), as well as the IPM group (c, d). Figure S2: IPM subgroup comparisons based on primary tumor size ($\leq$3 cm vs. 3-5 cm vs. >5 cm). Table S1: individualized diagnosis and treatment gene detection of the sMPLC group. Table S2: individualized diagnosis and treatment gene detection of the IPM group. Table S3: comparison of $\Delta$SUV$_{max}$/$D_{max}$ and $\Delta K_r$/$D_{max}$ between different age groups. Table S4: internal validation by Bootstrap. (Supplementary Materials)

References

[1] M. May, “Statistics: attacking an epidemic,” Nature, vol. 509, no. 7509, pp. 550–551, 2014.
[2] B. D. Kozower, J. M. Larner, F. C. Detterbeck, and D. R. Jones, “Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 143, no. 5, pp. e369s–e399s, 2013.
[3] N. Martini and M. R. Melamed, “Multiple primary lung cancers,” The Journal of Thoracic and Cardiovascular Surgery, vol. 70, no. 4, pp. 606–612, 1975.
[4] Y. Takahashi, K. Shien, S. Tomida et al., “Comparative mutational evaluation of multiple lung cancers by multiplex onco-gene mutation analysis,” Cancer Science, vol. 109, no. 11, pp. 3634–3642, 2018.
[5] D. Pinkel and D. G. Albertson, “Array comparative genomic hybridization and its applications in cancer,” Nature Genetics, vol. 37, no. 6, pp. S11–S17, 2005.
[6] I. Scheinin, D. Sie, H. Bengtsson et al., “DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly,” Genome Research, vol. 24, no. 12, pp. 2022–2032, 2014.
[7] M. T. van Rens, E. J. Eijken, J. R. Elbers, J. W. Lammers, M. G. Tilanus, and P. J. Slootweg, “p53 mutation analysis for definite diagnosis of multiple primary lung carcinoma,” Cancer, vol. 94, no. 1, pp. 188–196, 2002.
[8] F. C. Detterbeck, W. A. Franklin, A. G. Nicholson et al., “The IASLC lung cancer staging project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer,” Journal of Thoracic Oncology, vol. 11, no. 5, pp. 651–665, 2016.
[9] M. K. Gould, C. C. Maclewan, W. G. Kuschner, C. E. Rydzak, and D. K. Owens, “Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis,” JAMA, vol. 285, no. 7, pp. 914–924, 2001.

[10] Y. L. Lv, D. M. Yuan, K. Wang et al., “Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis,” Journal of Thoracic Oncology, vol. 6, no. 8, pp. 1350–1358, 2011.

[11] H. Y. Lee, H. J. Lee, Y. T. Kim et al., “Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 5, no. 4, pp. 497–503, 2010.

[12] H. J. Im, K. Pak, G. J. Cheon et al., “Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 42, no. 2, pp. 241–251, 2015.

[13] M. Muzi, F. O'Sullivan, D. A. Mankoff et al., “Quantitative assessment of dynamic PET imaging data in cancer imaging,” Magnetic Resonance Imaging, vol. 30, no. 9, pp. 1203–1215, 2012.

[14] H. Vesselle, A. Salskov, E. Turcotte et al., “Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index,” Journal of Thoracic Oncology, vol. 3, no. 9, pp. 971–978, 2008.

[15] L. F. de Geus-Oei, J. H. van Krieken, R. P. Alredjio et al., “Biological correlates of FDG uptake in non-small cell lung cancer,” Lung Cancer, vol. 55, no. 1, pp. 79–87, 2007.

[16] K. Higashi, Y. Ueda, K. Ayabe et al., “FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features,” Nuclear Medicine Communications, vol. 21, no. 8, pp. 707–714, 2000.

[17] R. J. Cerfolio, A. S. Bryant, B. Ohja, and A. A. Bartolucci, “The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival,” The Journal of Thoracic and Cardiovascular Surgery, vol. 130, no. 1, pp. 151–159, 2005.

[18] S. Shiono, M. Abiko, and T. Sato, “Positron emission tomography/computed tomography and lymphovascular invasion predict recurrence in stage I lung cancers,” Journal of Thoracic Oncology, vol. 6, no. 1, pp. 43–47, 2011.

[19] V. J. Lowe, D. M. DeLong, J. M. Hoffman, and R. E. Coleman, “Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy,” Journal of Nuclear Medicine, vol. 36, no. 5, pp. 883–887, 1995.

[20] R. Boelhaar, N. C. Krak, O. S. Hoekstra, and A. A. Lammertsma, “Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study,” Journal of Nuclear Medicine, vol. 45, no. 9, pp. 1519–1527, 2004.

[21] C. J. Jaskowiak, J. A. Bianco, S. B. Perlman, and J. P. Fine, “Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values,” Journal of Nuclear Medicine, vol. 46, no. 3, pp. 424–428, 2005.

[22] F. N. Roy, S. Beaulieu, L. Boucher, I. Bourdeau, and C. Cohade, “Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients,” Journal of Nuclear Medicine, vol. 50, no. 2, pp. 178–183, 2009.

[23] R. L. Wahl, C. A. Henry, and S. P. Ethier, “Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma,” Radiology, vol. 183, no. 3, pp. 643–647, 1992.

[24] G. Antoch, H. Kuehl, J. Kanja et al., “Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation,” Radiology, vol. 230, no. 3, pp. 879–885, 2004.

[25] C. S. Patlak, R. G. Blasberg, and J. D. Fenstermacher, “Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data,” Journal of Cerebral Blood Flow & Metabolism, vol. 3, no. 1, pp. 1–7, 1983.

[26] C. S. Patlak and R. G. Blasberg, “Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations,” Journal of Cerebral Blood Flow & Metabolism, vol. 5, no. 4, pp. 584–590, 1985.

[27] A. A. Lammertsma, C. J. Hoekstra, G. Giaccone, and O. S. Hoekstra, “How should we analyse FDG PET studies for monitoring tumour response?,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, Supplement 1, pp. 16–21, 2006.

[28] C. J. Hoekstra, I. Pagliarini, O. S. Hoekstra et al., “Monitoring response to therapy in cancer using [ 18 F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods,” European Journal of Nuclear Medicine, vol. 27, no. 6, pp. 731–743, 2000.

[29] P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment of cancer. National Cancer Institute of the United States, National Cancer Institute of Canada,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000.

[30] M. Yang, Z. Lin, Z. Xu et al., “Influx rate constant of 18F-FDG increases in metastatic lymph nodes of non-small cell lung cancer patients,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. 5, pp. 1198–1208, 2020.

[31] L. Jiang, J. He, X. Shi et al., “Prognosis of synchronous and metachronous multiple primary lung cancers: systematic review and meta-analysis,” Lung Cancer, vol. 87, no. 3, pp. 303–310, 2015.

[32] D. Trousse, F. Barlesi, A. Loundou et al., “Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management,” The Journal of Thoracic and Cardiovascular Surgery, vol. 133, no. 5, pp. 1193–1200, 2007.

[33] F. C. Detterbeck, V. Bolejack, D. A. Arenberg et al., “The IASLC lung cancer staging project: background data and proposals for the classification of lung cancer with separate tumor nodules in the forthcoming eighth edition of the TNM classification for lung cancer,” Journal of Thoracic Oncology, vol. 11, no. 5, pp. 681–692, 2016.

[34] R. Ramí-Porta, V. Bolejack, J. Crowley et al., “The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer,” Journal of Thoracic Oncology, vol. 10, no. 7, pp. 990–1003, 2015.

[35] N. Girard, C. Deshpande, C. Lau et al., “Comprehensive histologic assessment helps to differentiate multiple lung primary non-small cell carcinomas from metastases,” The American Journal of Surgical Pathology, vol. 33, no. 12, pp. 1752–1764, 2009.

[36] A. Hattori, T. Matsunaga, K. Takamochi, S. Oh, and K. Suzuki, “Radiological classification of multiple lung cancers and the prognostic impact based on the presence of a ground glass
opacity component on thin-section computed tomography,” *Lung Cancer*, vol. 113, pp. 7–13, 2017.

[37] J. A. Obando, J. M. Samii, and M. Yasrebi, “A case of two synchronous primary lung tumors demonstrated by FDG positron emission tomography,” *Clinical Nuclear Medicine*, vol. 33, no. 11, pp. 775–777, 2008.

[38] C. Liu, Y. X. An, L. J. Ma, and X. J. Zhang, “Early multiple primary lung cancer without fluorodeoxyglucose uptake on positron emission tomography-computed tomography and displaying different EGFR molecular profiles,” *Chinese Medical Journal*, vol. 130, no. 22, pp. 2763–2764, 2017.

[39] L. Pang, G. Liu, H. Shi, P. Hu, B. Li, and D. Cheng, “Nine-teen cases with synchronous multiple primary 18 cancers studied by F-FDG PET/CT,” *Hellenic Journal of Nuclear Medicine*, vol. 20, no. 1, pp. 36–40, 2017.

[40] T. Derlin, T. S. Clauditz, A. Quaas, and C. R. Habermann, “Synchronous bronchioalveolar and squamous cell lung cancer with different 18F-FDG avidity on PET/CT,” *Clinical Nuclear Medicine*, vol. 37, no. 10, pp. e255–e256, 2012.

[41] N. Kosaka, T. Tsuchida, K. Tsuji, K. Shimizu, and H. Kimura, “Standardized uptake value differences between primary and metastatic lesions in18F-FDG PET/CT of patients with lung cancer,” *Acta Radiologica*, vol. 56, no. 11, pp. 1329–1335, 2015.

[42] Y. Liu, Y. Tang, Z. Xue et al., “SUVmax ratio on PET/CT may differentiate between lung metastases and synchronous multiple primary lung cancer,” *Academic Radiology*, vol. 27, no. 5, pp. 618–623, 2020.

[43] H. H. Hsu, K. H. Ko, Y. C. Chou et al., “SUVmax and tumor size predict surgical outcome of synchronous multiple primary lung cancers,” *Medicine (Baltimore)*, vol. 95, no. 6, article e2351, 2016.

[44] Y. L. Chang, C. T. Wu, and Y. C. Lee, “Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients,” *The Journal of Thoracic and Cardiovascular Surgery*, vol. 134, no. 3, pp. 630–637, 2007.

[45] F. C. Detterbeck, D. J. Boffa, A. W. Kim, and L. T. Tanoue, “The eighth edition lung cancer stage classification,” *Chest*, vol. 151, no. 1, pp. 193–203, 2017.

[46] G. Liu, H. Yu, D. Shi et al., “Short-time total-body dynamic PET imaging performance in quantifying the kinetic metrics of 18F-FDG in healthy volunteers,” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 49, no. 8, pp. 2493–2503, 2022.

[47] G. Liu, H. Xu, P. Hu et al., “Kinetic metrics of 18F-FDG in normal human organs identified by systematic dynamic total-body positron emission tomography,” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 48, no. 8, pp. 2363–2372, 2021.

[48] M. Soret, S. L. Bacharach, and I. Buvat, “Partial-volume effect in PET tumor imaging,” *Journal of Nuclear Medicine*, vol. 48, no. 6, pp. 932–945, 2007.